Literature DB >> 10201630

An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link.

W Debinski1.   

Abstract

Human high-grade gliomas (HGG) are one of the most devastating human malignancies. They are rapidly progressing heterogenous tumors for which no curable treatment is available. Although these tumors are believed to be of glial cell origin, known tumor-specific markers do not characterize them. The specific environmental conditions that cause or promote the development of HGG are not known. The pathomechanism of HGG is yet to be revealed, although more specific genetic alterations are assigned to HGG. Recently, we have found that HGG overexpress a receptor for an immune regulatory cytokine, interleukin-13 (IL-13). In fact, it appears that all patients with glioblastoma multiforme may possess this receptor. IL-13 is an antiinflammatory cytokine with many overlapping functions to its homologue, IL-4. There is a high degree of specificity of the overexpression of the IL-13 receptor in HGG. This receptor is not only quantitatively but also qualitatively different from the only known functional signaling receptor for IL-13 of normal tissue. It is not shared with IL-4. The more restrictive receptor for IL-13 thus may represent a new factor specific for a disease as heterogenous as HGG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10201630

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  14 in total

1.  When better still might not be good enough.

Authors:  Waldemar Debinski
Journal:  Transl Cancer Res       Date:  2017-10       Impact factor: 1.241

Review 2.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction.

Authors:  Guoying Zhou; Guo-Jie Ye; Waldemar Debinski; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

4.  Novel Molecular Multilevel Targeted Antitumor Agents.

Authors:  Poonam Sonawane; Young A Choi; Hetal Pandya; Denise M Herpai; Izabela Fokt; Waldemar Priebe; Waldemar Debinski
Journal:  Cancer Transl Med       Date:  2017-06-08

5.  Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.

Authors:  Guoying Zhou; Bernard Roizman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.

Authors:  A B Madhankumar; Akiva Mintz; Waldemar Debinski
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

7.  Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.

Authors:  Akiva Mintz; Denise M Gibo; A B Madhankumar; Nancy M Cladel; Neil D Christensen; Waldemar Debinski
Journal:  Cancer Biother Radiopharm       Date:  2008-10       Impact factor: 3.099

8.  Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.

Authors:  Akiva Mintz; Denise M Gibo; A B Madhankumar; Waldemar Debinski
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

9.  A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Authors:  Van Nguyen; Jesse M Conyers; Dongqin Zhu; Denise M Gibo; Roy R Hantgan; Steven M Larson; Waldemar Debinski; Akiva Mintz
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

Review 10.  Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.

Authors:  Edward Rustamzadeh; Chunbin Li; Sekou Doumbia; Walter A Hall; Daniel A Vallera
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.